UNSPSC 51171722: Diphenoxylate hydrochloride

This classification denotes an opioid analgesic and antidiarrheal with the molecular formula C30H32N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W24OD7YW48, chemically known as 2,2-diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile but more generally known as diphenoxylate hydrochloride, which bears US NIH Compound Identifier 13505. European Medicines Agency schedules Diphenoxylate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01776MIG.

UNSPSC 51171722 Diphenoxylate hydrochloride is a Commodity code that does not reflect the primary work actually being solicited under it in recent state and local procurement activity. The three recent opportunities tagged to this code—offender drug testing services, a therapeutic pharmacy initiative direct-to-manufacturer prescription program exploration, and a multi-state cooperative purchasing agreement for generic pharmaceuticals and OTC products—do not center on diphenoxylate hydrochloride as a discrete pharmaceutical line item. The code's nominal scope covers a single controlled-substance opioid antidiarrheal, yet the solicitations are structured around broader drug testing program management, pharmacy benefit innovation, and multi-product generic pharmaceutical distribution. This mismatch suggests either tagging error or a catch-all classification for pharmacy-related procurements that does not align cleanly with the commodity code's intended product specificity.

If purchasing activity under this code is to be pursued, the geographic footprint and issuing-body pattern reflect Texas and multi-state cooperative purchasing vehicles. Collin County Community Supervision and Corrections Department (Texas) posted an RFP for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year initial term commencing September 1, 2026. The Texas Health and Human Services Commission issued a Request for Information on March 27, 2026 to explore direct-to-manufacturer prescription programs. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products serving state and local government facilities across multiple states including Oregon. The code shows marginal relevant recent activity, and suppliers evaluating this opportunity should verify whether their product or service alignment is correctly classified under this commodity code or whether upstream family or class codes would better capture state and local purchasing intent.